TOP HEADLINES

Editor's Corner

Analysts: Mylan won't land Perrigo, even with Teva out of the way

Teva's $40.5 billion deal to buy Allergan's generics business ended its pursuit of Mylan and left its rival the chance to snap up its own hostile target, Perrigo. But the way some analysts see it, things won't necessarily go that way.

Glaxo posts 'unremarkable' results in first quarter after Novartis swap

On Wednesday, GlaxoSmithKline announced results for its first full quarter after closing its blockbuster asset swap with Novartis. And so far, things look "unremarkable."

Pfizer drops effort to make Lipitor an OTC med

Millions of Americans take statins to help control their cholesterol and try to stay heart healthy. You just can't count on them to handle that on their own, Pfizer has found. And so the maker of Lipitor, the most successful statin of them all, has given up on its efforts to move the drug to an over-the-counter treatment.

Bayer's bets on consumer health deliver during Q2

Bayer CEO Marijn Dekkers bet that picking up Merck's consumer business last year would give his company a boost as it prepares to hive off its plastics unit and refocus on life sciences. Now Dekkers' gamble appears to be paying off, as the Leverkusen-based drugmaker beat analysts' estimates in Q2 with the help of its new consumer business and recent launches.

Sanofi looks to go to FDA in Q4 as diabetes combo LixiLan hits goal in trial

Sanofi has gotten a bit of positive reinforcement in its efforts to revive its diabetes business in the U.S. Experimental combo med LixiLan has thrown off some promising results, hitting its primary goal in a late-stage trial.

MORE NEWS

From Our Sister Sites

FierceAnimalHealth

Veterinary diagnostics maker Heska's stock has more than doubled since last year, but it's clearly experiencing some growing pains. On Wednesday, Heska missed analysts' sales targets for the second quarter, reporting year-over-year revenue growth of 4% to 23.9 million. Analysts had been expecting revenues of $24.3 million.

FierceVaccines

The world's biggest vaccine by sales--Prevnar 13--just keeps getting bigger. And in doing so, the shot helped Pfizer notch 44% vaccines growth for the second quarter as the unit saw sales grow from $1.09 billion in last year's Q2 to $1.58 billion during the period this year.